BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, et al. Breast Cancer Res Treat 2020 Apr 20. pii: 10.1007/s10549-020-05647.

Read + Share

Amedeo Smart

Independent Medical Education

Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Res Treat 2020 Apr 20. pii: 10.1007/s10549-020-05647.
PMID: 32314111